# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $43 pr...
BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data sho...
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, tod...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $43 pr...
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated...
Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $70 price ...
UBS analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $51 to $47.
The 2024 International Symposium on Amyloidosis (ISA) is taking place in Rochester, Minnesota on May 26 - 30, 2024.